December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Topical Glaucoma Medication Changes the Expression of CD95 in Human Tenon Fibroblasts
Author Affiliations & Notes
  • JM Esser
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • G Welsandt
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • N Kociok
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • C Esser
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • J Jordan
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • TT Luther
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • H Mietz
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • GK Krieglstein
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • P Esser
    Ophthalmology University Eye Clinic Cologne Cologne Germany
  • Footnotes
    Commercial Relationships   J.M. Esser, None; G. Welsandt, None; N. Kociok, None; C. Esser, None; J. Jordan, None; T.T. Luther, None; H. Mietz, None; G.K. Krieglstein, None; P. Esser, None. Grant Identification: DFG (Es 82/5-3, Mi 347/5-1), Köln Fortune program and Retinovit Foundation
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 3343. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      JM Esser, G Welsandt, N Kociok, C Esser, J Jordan, TT Luther, H Mietz, GK Krieglstein, P Esser; Topical Glaucoma Medication Changes the Expression of CD95 in Human Tenon Fibroblasts . Invest. Ophthalmol. Vis. Sci. 2002;43(13):3343.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose:Programmed cell death or apoptosis is a process, whereby developmental or environmental stimuli cause cell death, without causing reproliferation or inflammation. Recently we have identified several death receptors in tenon fibroblasts. ( TRAMP, TRAIL, CD95 ) Here we investigated, if the use of topical, glaucoma medication could change the expression of CD95L (Fas/Apo-1 ligand), one of the best known inductors of apoptosis Methods:Expression of CD95L was analyzed in surgically removed tenon tissues by immunohistochemistry. CD95L expression by cultured tenon fibroblasts pretreated with topical glaucoma drugs was assessed by flow cytometry. The general immunostaining procedures were performed as described previously. Surgical specimens were obtained from patients undergoing trabeculectomy for a variety of glaucomatous disorders. All patients gave informed consent prior to surgery. Flow Cytometry: Human Tenon Fibroblasts were treated with Timolol 0,5%, Pilocarpin 1% and Latanoprost 0,005% for 2 weeks on a subtoxic level. Afterwards, flow Cytometry was performed as described previously. The standardized fluorescence index (SFI) was calculated as the ratio of the mean fluorescence values obtained with the specific antibody and the isotype control antibody. Results:CD95L expression could be observed in most specimens. Flow cytometry revealed a marked increase of the CD95 expression for the prostaglandinderivat latanoprost (SFI=9,22) and for the ß-blocker Timoptol (SFI=8,50), in contrast to Pilocarpine-treated cells (SFI= 4,56) and the control (SFI= 4,50). Conclusion:Antiglaucomatous medication has often been shown to alter conjunctival tissue. Since reproliferation of tenon fibroblasts and therefore scarring and closure of filter blebs still is the main reason for failure of glaucoma surgery, induction of apoptosis could lead to a new way of treatment. Here we showed the important fact, that antiglaucomatous medication can alter apoptotic proteins and therefore influence treatments of glaucoma by proapoptotic drugs.

Keywords: 631 wound healing • 323 apoptosis/cell death • 365 conjunctiva 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×